Seres Therapeutics (NASDAQ:MCRB) Upgraded to Strong-Buy at HC Wainwright

HC Wainwright upgraded shares of Seres Therapeutics (NASDAQ:MCRB) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports. HC Wainwright also issued estimates for Seres Therapeutics’ Q2 2026 earnings at ($2.07) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($5.84) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at ($3.03) EPS.

A number of other equities research analysts also recently issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and set a $22.00 price target on shares of Seres Therapeutics in a research report on Friday, March 13th. Wall Street Zen upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Seres Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Seres Therapeutics Price Performance

MCRB opened at $7.05 on Tuesday. The stock has a market capitalization of $68.24 million, a price-to-earnings ratio of -1.36 and a beta of 0.13. The business has a 50-day moving average of $7.46 and a two-hundred day moving average of $10.67. Seres Therapeutics has a 12 month low of $5.31 and a 12 month high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.36 million.

Institutional Trading of Seres Therapeutics

Large investors have recently bought and sold shares of the company. Invesco Ltd. lifted its position in shares of Seres Therapeutics by 37.5% during the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 3,918 shares in the last quarter. 683 Capital Management LLC acquired a new position in shares of Seres Therapeutics in the fourth quarter worth about $778,000. ExodusPoint Capital Management LP purchased a new position in Seres Therapeutics in the fourth quarter valued at about $190,000. OMERS ADMINISTRATION Corp purchased a new stake in Seres Therapeutics during the 4th quarter worth approximately $214,000. Finally, Barclays PLC raised its position in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 6,024 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.